Patrick G. LePore, a director at VYNE Therapeutics Inc. (NASDAQ:VYNE), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on January 15, 2025 ...

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), with a price target of $8.00. The company’s shares closed ...

VYNE Therapeutics has completed enrollment for its Phase 2b trial of VYN201 gel, now named repibresib, for treating nonsegmental vitiligo, with top-line results expected in mid-2025. This clinical ...

TD Cowen analyst Stacy Ku maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $5.00. The ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with ...

VYNE Therapeutics Inc., a Delaware-based pharmaceutical company specializing in immuno-inflammatory conditions, recently made key updates in its corporate presentation. On January 13, 2025 ...

US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as repibresib, for treating non-segmental vitiligo.

4 analysts have expressed a variety of opinions on VYNE Therapeutics (NASDAQ:VYNE) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with ...

BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated ...